These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38780884)

  • 21. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
    Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
    Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.
    Breton MC; Huang L; Snedecor SJ; Cornelio N; Fanton-Aita F
    Can J Public Health; 2020 Apr; 111(2):182-192. PubMed ID: 31907760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
    Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
    J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.
    Banzhoff A
    Ther Adv Vaccines; 2017 Feb; 5(1):3-14. PubMed ID: 28344804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.
    Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L
    mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022.
    Rodrigues CMC; MacDonald L; Ure R; Smith A; Cameron JC; Maiden MCJ
    mBio; 2023 Apr; 14(2):e0049923. PubMed ID: 37036356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of invasive
    Sereikaitė E; Plepytė R; Petrutienė A; Stravinskienė D; Kučinskaitė-Kodzė I; Gėgžna V; Ivaškevičienė I; Žvirblienė A; Plečkaitytė M
    Front Cell Infect Microbiol; 2023; 13():1136211. PubMed ID: 36875527
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
    Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
    Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal Serogroup B Disease in Vaccinated Children.
    Soler-Garcia A; Fernández de Sevilla M; Abad R; Esteva C; Alsina L; Vázquez J; Muñoz-Almagro C; Noguera-Julian A
    J Pediatric Infect Dis Soc; 2020 Sep; 9(4):454-459. PubMed ID: 31634404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents.
    Biolchi A; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Budroni S; Giuliani MM; Rappuoli R; Boucher P; Pizza M
    Infect Dis Ther; 2021 Mar; 10(1):307-316. PubMed ID: 33185849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.